Showing 20 of 126 recruiting trials for “small-cell-lung-cancer”
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer with Leptomeningeal Disease
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
👨⚕️ Revolution Medicines, Inc., Revolution Medicines, Inc.📍 16 sites📅 Started May 2022View details ↗
Alectinib Pharmacokinetic in Patients With NSCLC
👨⚕️ Oscar G Arrieta Rodriguez, M.D., M.Sc., Instituto Nacional de Cancerologia de Mexico📍 1 site📅 Started May 2022View details ↗
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
👨⚕️ Wang Wang Jie M.D., Peking University Cancer Hospital & Institute📍 27 sites📅 Started Apr 2022View details ↗
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RecruitingNCT05621837 ↗
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
👨⚕️ Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori - Milan📍 1 site📅 Started Mar 2022View details ↗
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
👨⚕️ Katherine Tkaczuk, MD, University of Maryland, Baltimore📍 1 site📅 Started Feb 2022View details ↗
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
👨⚕️ Iovance Biotherapeutics Study Team, Iovance Biotherapeutics📍 84 sites📅 Started May 2021View details ↗
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
👨⚕️ Mark Vincent, MD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's📍 10 sites📅 Started Jan 2021View details ↗
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
RecruitingNCT04324164 ↗
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
RecruitingNCT04510129 ↗
A Multicenter Cancer Biospecimen Collection Study
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →